Severe Combined Immunodeficiency
Last Posted: Jul 21, 2022
- Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency
STF Shih et al, IJNS, July 20, 2022
- Lessons Learned from Five Years of Newborn Screening for Severe Combined Immunodeficiency (SCID) in Israel.
Lev Atar et al. The journal of allergy and clinical immunology. In practice 2022
- Severe Combined Immunodeficiency: Knowledge and Information Needs Among Healthcare Providers.
Kutsa Oksana et al. Frontiers in pediatrics 2022 10804709
- Study Design for an Evaluation of Newborn Screening for SCID in the UK.
Elliman David et al. International journal of neonatal screening 2022 8(1)
- Implementation of Universal Newborn Screening for Severe Combined Immunodeficiency in Singapore While Continuing Routine Bacille-Calmette-Guerin Vaccination Given at Birth.
Chan Su-Wan Bianca et al. Frontiers in immunology 2022 12794221
- Establishing Newborn Screening for SCID in the USA; Experience in California.
Puck Jennifer M et al. International journal of neonatal screening 2021 7(4)
- Future Perspectives of Newborn Screening for Inborn Errors of Immunity.
Blom Maartje et al. International journal of neonatal screening 2021 7(4)
- Genetic screening techniques and diseases for neonatal genetic diseases.
Han Lianshu et al. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2021 50(4) 429-435
- Economic Evaluation of Different Screening Strategies for Severe Combined Immunodeficiency Based on Real-Life Data.
van den Akker-van Marle M Elske et al. International journal of neonatal screening 2021 7(3)
- Evaluation of newborn screening for severe combined immunodeficiency (SCID).
Nightingale Rebecca et al. The British journal of general practice : the journal of the Royal College of General Practitioners 2021 71(711) 456-457
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
- CDC Information (3)
- NIH Information (8)
- COVID-19 (4)
- CDC Publications (2)
- Human Genome Epidemiologic Studies (8)
- Genomic Tests Evidence Synthesis (6)
- Genomic Tests Guidelines (3)
- Tier-Classified Guidelines (1)
- Pathogen Advanced Molecular Detection (5)
- State Public Health Genomics Programs (3)
- Reviews/Commentaries (53)
- Tools/Methods (1)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.